Stem cells for the treatment of early to moderate osteoarthritis of the knee: a systematic review

Journal of Experimental Orthopaedics

Review Paper

Ioannis Gigis¹  Charalampos Pitsilos¹  Konstantinos Ditsios¹  Alexandros Tzaveas²  Michael Iosifidis³  Theofylaktos Kyriakidis⁴  Myrto Iosifidou⁵ 

[1] 2nd Department of Orthopaedic Surgery and Traumatology, Aristotle University of Thessaloniki, “G. Gennimatas” General Hospital, Ethnikis Aminis 41, 54635, Thessaloniki, Hellas, Greece;3rd Orthopaedic Department, Interbalkan Medical Center, Thessaloniki, Greece;3rd Orthopaedic Department, Interbalkan Medical Center, Thessaloniki, Greece;Orthobiology Surgery Center, Thessaloniki, Greece;Department of Orthopaedic Surgery and Traumatology, Erasme University Hospital, Université Libre de Bruxelles, Route de Lennik 808, 1070, Brussels, Belgium;2nd Department of Orthopaedic Surgery and Traumatology, Aristotle University of Thessaloniki, “G. Gennimatas” General Hospital, Ethnikis Aminis 41, 54635, Thessaloniki, Hellas, Greece;3rd Orthopaedic Department, Interbalkan Medical Center, Thessaloniki, Greece;Orthobiology Surgery Center, Thessaloniki, Greece;

关键词: Knee osteoarthritis;    Outcomes;    PROMs;    Mesenchymal stem cells;    MSCs;    Regenerative medicine;    Intraarticular injection;   

DOI  :  10.1186/s40634-023-00665-1

 received in 2023-06-04, accepted in 2023-09-27,  发布年份 2023

来源: Springer

【 摘 要 】

PurposeMesenchymal stem cells (MSCs) present a valuable treatment option for knee osteoarthritis with promising results. The purpose of the present study was to systematically review the clinical and functional outcomes following mesenchymal stem cell application focusing on early to moderate knee osteoarthritis.MethodsA systematic search was done using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines in Pubmed, Scopus, Web of Science, and Cochrane Library databases. All Studies published between 2017 and March 2023 on patients treated with single mesenchymal stem cell injection for Kellgren-Lawrence grade I—III knee osteoarthritis reported on clinical and functional outcomes were included.ResultsTwelve articles comprising 539 patients and 576 knees treated with a single intraarticular injection of MSCs for knee osteoarthritis were included in the current systematic review. In eligible studies, the reported outcomes were improved concerning patient-reported outcomes measures, knee function, pain relief, and quality of patient's life.ConclusionBased on high-level evidence studies, single intraarticular injection of MSCs is a safe, reliable, and effective treatment option for Kellgren-Lawrence grade I—III knee osteoarthritis. However, the lack of homogeneity in the included studies and the variance in MSCs sources and preparations should be noted.Level of evidenceIII.

【 授权许可】

CC BY   
© European Society of Sports Traumatology, Knee Surgery, Arthroscopy (ESSKA) 2023

【 图 表 】

Fig. 2